

AMENDMENTS TO THE CLAIMS

Please cancel claims 18-20 and amend claim 1 as follows:

1. (currently amended) A process for prolonging in vivo expression of longer than seven days of a transgene nucleic acid sequence from a delivered expression ~~vector~~ cassette, comprising:
 - a) providing the expression cassette comprising the transgene nucleic acid sequence operably linked to a promoter;
 - b) forming a non-viral, linear DNA vector comprising the expression cassette; and,
 - c) delivering the non-viral, linear DNA vector to a hepatocyte in a mammal, wherein providing the expression cassette on the non-viral, linear DNA vector results in prolonging expression of longer than seven days of the transgene nucleic acid sequence in the hepatocyte.
2. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains blunt ends.
3. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains sticky ends.
4. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains a blunt end and a sticky end.
5. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is generated by restriction enzyme digestion.
6. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is generated by polymerase chain reaction.
7. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette isolated from a plasmid backbone.
8. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by sequence derived from inner Tn5 transposase recognition elements.

9. (previously presented) The process of claim 8, wherein the non-viral, linear DNA vector ends are blunt.
10. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by sequence derived from ~~inner~~ outer Tn5 transposase recognition elements.
11. (previously presented) The process of claim 10, wherein the non-viral, linear DNA vector ends are blunt.
12. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by chimeric ends derived from Tn5 transposase recognition elements.
13. (previously presented) The process of claim 12, wherein the non-viral, linear DNA vector ends are blunt.
14. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is delivered to cells intravascularly.
15. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector are delivered intravascularly using pressure.
16. (canceled)
17. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is delivered by direct interstitial injection.
18. (canceled) A process for prolonging *in vivo* expression of a transgene from a delivered expression vector, comprising:
 - a) generating a non-viral, linear DNA vector comprising a DNA expression cassette encoding the transgene; and,
 - b) delivering the linear DNA vector to a mammalian cell *in vivo*,
 - c) wherein delivery to the cell of the linear DNA vector provides for prolonging expressing of the transgene in the cell.
19. (canceled) The expression vector of claim 18, wherein the non-viral, linear DNA vector is prepared by restriction enzyme digestion.

20. (canceled) The expression vector of claim 18, wherein the non-viral, linear DNA vector is prepared by polymerase chain reaction.